Botulinum toxin injection and phenol nerve block for reduction of end-of-life pain

Journal of Palliative Medicine

Volumn 16, Issue 12, 2013, Pages 1637-1640

  Fu, Jack ^a   Ngo, An ^a   Shin, Ki ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DEXAMETHASONE; MODAFINIL; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; PHENOL; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; ANALGESIA; ANKLE; AROUSAL; ARTICLE; BICEPS BRACHII MUSCLE; BLEPHAROSPASM; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COGNITIVE DEFECT; CONSULTATION; DELIRIUM; DISEASE SEVERITY; DROWSINESS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSTONIA; ELECTROSTIMULATION; ENTERIC FEEDING; EXTENSOR MUSCLE; FEMALE; FLEXOR MUSCLE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPOAROUSAL; LATISSIMUS DORSI MUSCLE; MEIGE SYNDROME; MUSCLE SPASM; MUSCLE TONE; MYALGIA; NERVE BLOCK; PAIN ASSESSMENT; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; PHYSICAL MEDICINE; PLANTARIS MUSCLE; PROGNOSIS; QUADRICEPS FEMORIS MUSCLE; QUADRIPLEGIA; RADIATION DOSE FRACTIONATION; REHABILITATION CENTER; SCORING SYSTEM; SEXUAL AROUSAL DISORDER; SPASTICITY; TERMINAL CARE; TIBIAL NERVE; WAKEFULNESS; WEAKNESS;

BOTULINUM TOXINS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; MUSCLE SPASTICITY; NERVE BLOCK; PAIN; PHENOL; TERMINAL CARE;

EID: 84890384900     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2013.0182     Document Type: Article

References (24)

1. Simpson DM, Gracies JM, Graham HK, et al.: Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurol 2008;70:1691-1698.
2. Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43 Suppl 1:S9-S15.
3. Smith HS, Audette J, Royal MA: Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain 2002; 18:S147-S154.
4. Horn LJ, Singh G, Drabowski ER: Chemoneurolysis with phenol and alcohol: A "dying art" that merits revival. In: Brashear A, Elovic E (eds): Spasticity Diagnosis and Management. New York: Demos Medical, 2011, pp. 102-103.
5. Kheder A, Nair KP: Spasticity: Pathophysiology, evaluation and management. Pract Neurol 2012;12:289-298.
6. Aoki KR, Francis J: Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011;17 Suppl 1:S28-S33.
7. Soares A, Andriolo RB, Atallah AN, da Silva EM: Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev 2012;4:CD007533.
8. Wissel J, Muller J, Dressnandt J, et al.: Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-49.
9. Smith HS, Audette J, Royal MA: Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain 2002; 18:S147-S154.
10. Costa J, Espirito-Santo C, Borges A, et al.: Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005:CD004315.
11. Marco E, Duarte E, Vila J, et al.: Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehab Med 2007;39:440-447.
12. Lim JY, Koh JH, Paik NJ: Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, doubleblind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008;39:126-131.
13. Singh JA, Fitzgerald PM: Botulinum toxin for shoulder pain. Cochrane Database Syst Rev 2010:CD008271.
14. Argoff CE: A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18:S177-S181.
15. Ranoux D, Attal N, Morain F, Bouhassira D: Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-283.
16. Ellies M, Laskawi R, Tormahlen G, Gotz W: The effect of local injection of botulinum toxin A on the parotid gland of the rat: An immunohistochemical and morphometric study. J Oral Maxillofac Surg 2000;58:1251-1256.
17. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C: Up-todate report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003;61:454-457.
18. Bomeli SR, Desai SC, Johnson JT, Walvekar RR: Management of salivary flow in head and neck cancer patients: A systematic review. Oral Oncol 2008;44:1000-1008.
19. Corradino B, Di Lorenzo S, Moschella F: Botulinum toxin A for oral cavity cancer patients: In microsurgical patients BTX injections in major salivary glands temporarily reduce salivary production and the risk of local complications related to saliva stagnation. Toxins 2012;4: 956-961.
20. Laskawi R, Ellies M: The role of botulinum toxin in the management of head and neck cancer patients. Curr Opin Otolaryngol Head Neck Surg 2007;15:112-116.
21. Bruera E, Watanabe S: New developments in the assessment of pain in cancer patients. Support Care Cancer 1994;2: 312-318.
22. Nekolaichuk CL, Bruera E, Spachynski K, MacEachern T, Hanson J, Maguire TO: A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 1999;13:311-323.
23. Akin S, Durna Z: A comparative descriptive study examining the perceptions of cancer patients, family caregivers, and nurses on patient symptom severity in Turkey. Eur J Oncol Nurs 2013;17:30-37.
24. Wennman-Larsen A, Tishelman C,Wengstrom Y, Gustavsson P: Factors influencing agreement in symptom ratings by lung cancer patients and their significant others. J Pain Symptom Manage 2007;33:146-155.